Xanilax SR 200 Tablet contains Acebrophylline 200 mg as its active ingredient, a bronchodilator and mucolytic agent primarily indicated for the management of respiratory conditions characterized by bronchospasm and excessive mucus production, such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. Acebrophylline acts by relaxing the smooth muscles of the airways, thereby facilitating bronchodilation and improving airflow. Additionally, it exhibits mucoregulatory properties by reducing mucus viscosity and enhancing mucociliary clearance, which aids in the effective expectoration of secretions. Xanilax SR 200 is formulated as a sustained-release tablet, ensuring prolonged therapeutic effects and improved patient compliance through reduced dosing frequency. The medication is generally well-tolerated; however, it should be used with caution in patients with hypersensitivity to xanthine derivatives, cardiovascular disorders, or peptic ulcers. Common adverse effects may include gastrointestinal discomfort, headache, and mild tachycardia. It is contraindicated in patients with known hypersensitivity to Acebrophylline or related compounds. Dosage and duration of therapy should be individualized based on clinical response and severity of the condition. Xanilax SR 200 should be used under medical supervision, and patients are advised to report any unusual symptoms promptly.